BRUSSELS (Alliance News) - The European Commission on Thursday said it has approved the acquisition of the Nimenrix and Mencevax vaccines businesses belonging to GSK of the UK by an Irish subsidiary of Pfizer of the US, under the EU Merger Regulation.
Both vaccines protect against meningitis A, C, W and Y. GSK, a global pharmaceutical, consumer health and vaccines company, committed to divest the vaccines to gain the Commission's clearance of its transaction with Novartis in January 2015.
Pfizer is a global pharmaceutical company which manufactures and sells a wide range of pharmaceuticals, including vaccines.
The Commission concluded that the proposed acquisition would raise no competition concerns because of the absence of overlap between the parties.
The present transaction was examined under the simplified merger review procedure.
Copyright RTT News/dpa-AFX
Glaxosmithkline (GSK)